BioMark Diagnostics to Present Liquid Biopsy Platform at the Canadian Thoracic Society Research Forum
BioMark Diagnostics to Present Liquid Biopsy Platform at the Canadian Thoracic Society Research Forum BioMark Comprehensive Metabolomics Assay Selected asTop Canadian Innovation for the CTS Beaver Den Innovation Award VANCOUVER, BRITISH COLUMBIA – (April 14, 2026) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF), a leading developer of liquid […]
BioMark Diagnostics Announces Publication of Peer-Reviewed Validation of Machine Learning Models for Lung Cancer Detection in Frontiers in Oncology
BioMark Diagnostics Announces Publication of Peer-Reviewed Validation of Machine Learning Models for Lung Cancer Detection in Frontiers in Oncology Advancing Superior Accuracy in Early Lung Cancer Detection Using Selective Metabolic Pathways and Data Enrichment for Enhanced Diagnostic Capabilities Vancouver, British Columbia – (January 15, 2026) — BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF), […]
BioMark Diagnostics Announces Appointment of Mr. James Lavender to Board of Directors
BioMark Diagnostics Announces Appointment of Mr. James Lavender to Board of Directors Expanding U.S. market access with an experienced technology investor and AI-driven growth strategist VANCOUVER, BRITISH COLUMBIA – (December 30, 2025) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF), a leading developer of liquid biopsy technologies for early […]
BioMark: 2025 Achievements & 2026 Vision
BioMark: 2025 Achievements & 2026 Vision Celebrating A Year of Extraordinary Achievement VANCOUVER, BRITISH COLUMBIA – (December 31, 2025) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF), a leading developer of liquid biopsy technologies for early cancer detection, today issued a Year-End Letter to Shareholders and Team from its […]
BioMark Diagnostics Advances Commercialization Strategy by Initiating ISO 15189 Accreditation Program
BioMark Diagnostics Advances Commercialization Strategy by Initiating ISO 15189 Accreditation Program Company engages Standards Council of Canada; targets ISO 15189 accreditation for early 2026 Vancouver, British Columbia – (December 23, 2025) – BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF), a leading developer of liquid biopsy technologies for early cancer detection, is pleased to […]
BioMark Diagnostics Collaborative Lung Cancer Screening Project Honored by ADRIQ during the 35th Innovation Awards Gala
Recognition of BioMark Leadership in Early Cancer Detection Validates Commercialization Trajectory of Multimodal Lung Cancer Screening Platform Vancouver, British Columbia – (December 1st, 2025) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF), a leading developer of liquid biopsy technologies for early cancer detection, is honored to announce that the Company and its […]
BioMark Aligns with National Strategy to Slash Lung Cancer Mortality with Next-Gen Liquid Biopsy
Next-generation metabolomics and AI technology supports the 2026 – 2035 Pan-Canadian Lung Cancer Action Plan’s call to expand equitable access to life-saving early diagnosis Vancouver, British Columbia – (November 12, 2025) – November is Lung Cancer Awareness Month, and BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF), a leading developer of liquid biopsy […]
BioMark’s Liquid Biopsy Platform Selected for Holistic German Lung Cancer Screening Trial
BioMark’s Liquid Biopsy Platform Selected for Holistic German Lung Cancer Screening Trial Extensive Validation of BioMark’s Comprehensive Metabolic Panel in German 10,000-Participant HANSE Study, within the context of an international consortium supported under the EUREKA Network. Vancouver, British Columbia – (October 7, 2025) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF), a […]
BioMark Secures Key Patents in Asia’s Largest Markets for Early Lung Cancer Liquid Biopsy
BioMark Secures Key Patents in Asia’s Largest Markets for Early Lung Cancer Liquid Biopsy Pioneering liquid biopsy platform for early lung cancer detection strengthens IP and accelerates commercial strategy in China and Japan diagnostic markets. Vancouver, British Columbia – (September 29, 2025) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF), a leading […]
BioMark Diagnostics Establishes African Market Presence Through Strategic Tunisia Healthcare Partnership
BioMark Diagnostics Establishes African Market Presence Through Strategic Tunisia Healthcare Partnership Proof-of-Concept Trial Opens Door to 90+ Million Population Across North Africa and Francophone Markets Vancouver, British Columbia – (August 12, 2025) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF), a leading developer of liquid biopsy tests for early cancer detection, announced […]